PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs

Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). However, intrinsic or acquired resistance remains a clin...

Full description

Bibliographic Details
Main Authors: Nadiia Lypova, Susan M. Dougherty, Lilibeth Lanceta, Jason Chesney, Yoannis Imbert-Fernandez
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cells
Subjects:
autophagy flux
lung cancer
epidermal growth factor receptor (EGFR)
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)
cytoprotective autophagy
Online Access:https://www.mdpi.com/2073-4409/10/7/1679

Similar Items

Similar Items